List of Antibodies Companies in Austria - 7

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodeler) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer. This “Active Checkpoint Control Immunotherapy” activates all four naturally available tumour killing mechanisms of the immune system without triggering side effects. The company’s lead candidate OQR100 (TYG100), co-developed with TYG Oncology Ltd. and CR-UK, targets pancreatic cancer and induces neutralizing antibodies against gastrin, a major growth factor for pancreatic- and other forms of gastric cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG and IgA) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing.

Let's write the future of DNA. Ribbon Biolabs is a biotech start-up working on developing the next technological wave of error-proof DNA synthesis. With its approach, company is developing a cost-efficient platform to produce long and complex DNA molecules, thereby enabling a new generation of biopharmaceutical processes and other synthetic biology products. Our international and highly motivated team located in Vienna is constantly looking for new talents who can join this exciting ride and take Ribbon Biolabs to the next level.

VelaLabs - founded 2006 - is a GLP and GMP-certified and G(C)LP compliant contract laboratory focusing on analytical and quality services of biopharmaceutical products supporting BIOTECH and PHARMA companies in the clinical development of biosimilars, biologics and ATMPs. By the acquisition of LABH in 2019 and building a clean room in 2020, VelaLabs also offers all types of microbiological services. Together with its strong team, the VelaLabs Management aims to successfully realize its vision of being a trusted partner for our customers along the process of medication development.